FENNEC PHARMACEUTICALS INC
For the period ended Mar 21, 2024. Filed Mar 25, 2024.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Mar 21, 2024 · Filed Mar 25, 2024
Use the contents to explore the available documents and sections.
FENC$9.81+4.5%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · Recent Developments and Highlights:
Recent Developments and Highlights:
| · | Entered into exclusive licensing agreement to commercialize PEDMARQSI™ in Europe, Australia and New Zealand. Fennec received approximately $43 million upfront and has the potential to receive up to approximately $230 million in additional commercial and regulatory milestones, and double-digit tiered royalties up to the mid-twenties. PEDMARQSI was granted EU marketing authorization by the European Commission in June 2023, and received UK approval from the MHRA in October 2023. |
| · | Achieved PEDMARK net product revenue of approximately $9 million and $21 million for the fourth quarter and full year 2023, respectively. Additionally, anticipate continued increasing utilization of the earlier endorsement from the NCCN for PEDMARK® in the adolescent and young adult (AYA) population. |
| · | In January 2024, the FDA issued a public reminder to healthcare providers that PEDMARK (sodium thiosulfate injection) is not substitutable with other sodium thiosulfate products as explicitly directed in its prescribing label. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.